Search

Displaying results 3101 - 3110 of 10000 in total
  1. Drug

    Hyaluronidase

    go.drugbank.com/drugs/DB14740
    ApprovedInvestigational

    Hyaluronidase is an enzyme used to improve the absorption and dispersion of parenterally administered fluids, drugs, and contrast agents. … [A199026] Early research into hyaluronidase identified it as a "spreading factor" which allowed for increased permeability of the connective tissue.

    Products: POLVO LIOFILIZADO PARA RECONSTITUIR A SOLUCION PARA ADMINISTRACIÓN OFTALMICA
  2. Drug

    Anifrolumab

    go.drugbank.com/drugs/DB11976
    ApprovedInvestigational

    [A237054] The design of early clinical trials of anti-interferon treatments such as anifrolumab, rontalizumab, and sifalimumab have come under criticism. … Anifrolumab, or MEDI-546, is a type 1 interferon receptor (IFNAR) inhibiting IgG1κ monoclonal antibody indicated in the treatment of adults with moderate to severe systemic lupus erythematosus.

    Products: Saphnelo 300 mg/2 mL İnfüzyonluk Çözelti Hazırlamak İçin Konsantre, 1 ADET
  3. Drug

    Cyanocobalamin Co-60

    go.drugbank.com/drugs/DB09387
    ApprovedWithdrawn

    Cyanocobalamin Co-60 is an analog of Vitamin B12 labeled with Co60. … Cyanocobalamin Co-60 was used for the diagnosis of pernicious anemia, but now it is withdrawn from the market in the US for unknown reasons.

  4. Drug

    Bardoxolone methyl

    go.drugbank.com/drugs/DB05983
    Investigational

  5. Drug

    Vanillyl butyl ether

    go.drugbank.com/drugs/DB11299
    Approved

    Vanillyl butyl ether is an ether of monohydroxybenzoic acid. It is added to food products as a flavoring agent. … It is also present in cosmetics and personal care products as a fragrance ingredient, oral care agent, hair conditioning agent, and warming or cooling agent.

  6. Drug

    Bitolterol

    go.drugbank.com/drugs/DB00901
    ApprovedWithdrawn

    It is a beta-2-adrenergic receptor agonist. Bitolterol was withdrawn from the market by Elan Pharmaceuticals in 2001.

  7. Drug

    Istisociclib

    go.drugbank.com/drugs/DB21703
    Investigational

    Istisociclib is under investigation in clinical trial NCT04718675 (A Study of KB-0742 in Participants With Relapsed or Refractory Solid Tumors Including Platinum Resistant High Grade Serous Ovarian Cancer … Istisociclib has a monoisotopic molecular weight of 287.21 Da.

  8. Drug

    TGAAC09

    go.drugbank.com/drugs/DB06363
    Investigational

    tgAAC09 is an investigational vaccine that utilizes an AAV vector to deliver genes that encode HIV proteins. … It was under investigation in clinical trials NCT00482027 and NCT00888446 for the treatment of HIV Infection.

  9. Drug

    Mefloquine

    go.drugbank.com/drugs/DB00358
    Approved

    Malaria is a protozoan disease that places an enormous burden on human health in endemic areas around the world. … [L30623] Mefloquine, commonly known as Lariam, is an antimalarial drug used for the prevention and treatment of malaria caused by infection with Plasmodium vivax and Plasmodium falciparum.

  10. Drug

    Tolrestat

    go.drugbank.com/drugs/DB02383
    ApprovedWithdrawn

    Tolrestat (INN) (AY-27773) is an aldose reductase inhibitor which was approved for the control of certain diabetic complications. … It was sold under the tradename Alredase but was discontinued by Wyeth in 1997 because of the risk of severe liver toxicity and death.